Bristol Myers Squibb (BMY)

[chmcnfunds]

Bristol-Myers and Clovis to evaluate Opdivo/Rubraca combo in range of tumors; Clovis down 6% premarket

Jul. 31, 2017 7:44 AM ET|About: Bristol-Myers Squibb C... (BMY)|By: Douglas W. House, SA News Editor

Bristol-Myers Squibb (NYSE:BMY) and Clovis Oncology (NASDAQ:CLVS) ink a clinical collaboration agreement to evaluate the combination of PD-1 inhibitor Opdivo (nivolumab) and PARP inhibitor Rubraca (rucaparib) across multiple tumor types.

Phase 3 studies will be conducted in advanced ovarian cancer and advanced triple-negative breast cancer. The partnership will also include a Phase 2 clinical trial in metastatic castration-resistant prostate cancer.

Clovis will sponsor and run the ovarian cancer trial while Bristol-Myers will be responsible for the prostate cancer and breast cancer studies. All three should commence before year-end.

CLVS is down 6% premarket on modestly higher volume. Shares rallied over 15% last week as investors were anticipating good news, possibly a buyout.
________________________________________________________
https://seekingalpha.com/news/3283265-bristol-myers-clovis-evaluate-opdivo-rubraca-combo-range-tumors-clovis-6-percent-premarket?app=1&uprof=46#email_link

BMY